

RESEARCH MONOGRAPH . COMPOUND PROFILE

Tropisetron

A serotonergic indolylcarboxylate ester developed at Sandoz as a chemotherapy-induced antiemetic, distinguished from other setrons by intrinsic partial agonist activity at the alpha-7 nicotinic acetylcholine receptor and downstream cognitive, anti-inflammatory, and analgesic activity.

DOCUMENT	KDC-MN-1351
ISSUED	2026-05-10
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	Selective 5-HT ₃ receptor antagonist with alpha-7 nicotinic acetylcholine receptor partial agonism

ABSTRACT

Tropisetron, the indol-3-carboxylate ester of tropine and the third selective 5-hydroxytryptamine type 3 (5-HT₃) receptor antagonist introduced for the management of chemotherapy-induced and postoperative nausea and vomiting, is a clinically marketed antiemetic in approximately 50 jurisdictions outside the United States and a research compound of escalating interest in cognition, central nervous system inflammation, fibromyalgia, and Alzheimer's disease. Distinct from ondansetron and granisetron in pharmacology though not in marketed indication, tropisetron is a dual-mechanism agent: at the 5-HT₃ ligand-gated cation channel it produces insurmountable, low-nanomolar antagonism with approximately 1000-fold selectivity over other monoamine receptors, while at the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor it acts as a potent partial agonist with low-micromolar functional activity in heterologous expression systems and in cortical and hippocampal neurons. The alpha-7 nicotinic activity, first formally characterized in the seminal Macor et al. (2001) report and subsequently extended by the Hashimoto laboratory in mouse models of phencyclidine-induced cognitive deficit and DBA/2 P50 auditory gating dysfunction, distinguishes tropisetron sharply from the other clinically marketed setrons and underwrites a research literature that now spans schizophrenia cognitive endpoints, fibromyalgia analgesia, refractory pruritus, ocular and pulmonary inflammation, postoperative neurocognitive recovery, and a Spilman et al. (2014) demonstration that tropisetron also binds the ectodomain of amyloid precursor protein at submicromolar affinity and normalizes cognition in the J20

transgenic mouse model of Alzheimer's disease at a human-equivalent oral dose of approximately 5 mg per day. Pharmacokinetics in humans are dominated by hepatic CYP2D6-mediated ring hydroxylation, producing a striking polymorphic phenotype: in extensive metabolizers, the plasma elimination half-life after a 5 mg oral dose is approximately 5 to 8 hours, while in CYP2D6 poor metabolizers the half-life extends to 30 to 40 hours and steady-state plasma concentrations approach an order of magnitude greater on chronic dosing, a finding that has both safety and dose-response implications. The compound is well tolerated at registered doses; the principal short-term adverse events are dose-dependent constipation, headache, and transient hypertension, and rare clinically significant arrhythmia is captured in pooled postmarketing data and prescribing labels. This monograph reviews the chemistry, synthesis, and stereochemistry of tropisetron; the dual-receptor pharmacology in molecular and electrophysiological detail; the comprehensive human pharmacokinetic record including CYP2D6 polymorphism; the clinical evidence base across antiemetic, fibromyalgia, schizophrenia cognitive, Alzheimer's disease, tinnitus, and inflammatory indications; the reconstitution, sourcing, and stack-interaction considerations for laboratory work; and a comparative assessment of five α -7 nicotinic acetylcholine receptor candidates against tropisetron on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by the United States Food and Drug Administration. It is sold as a research-grade preparation outside its marketed antiemetic application; investigators should obtain analytical confirmation of identity and purity on every lot.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Tropisetron.

Marketed names: Navoban (Novartis; Australia, New Zealand, Japan, the Republic of Korea, the Philippines, several European Union member states), Setrovel (generic markets), Navotron (generic), Trogosan (generic).

Development codes: ICS 205-930 (Sandoz). The development code is the canonical identifier in the early pharmacology literature and the only identifier on which the seminal Macor et al. (2001) characterization of alpha-7 nicotinic partial agonism was carried out [1].

Chemical Abstracts Service registry numbers: 89565-68-4 (free base), 105826-92-4 (hydrochloride salt). The free base is the synthetic and pharmacopoeial form; the hydrochloride is the formulated salt for oral and intravenous preparations.

International Union of Pure and Applied Chemistry name: (1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1H-indole-3-carboxylate. The compound is the indol-3-carboxylate ester of tropine (the 3- α -hydroxy isomer of the 8-methyl-8-azabicyclo[3.2.1]octane ring system shared with cocaine, atropine, and several other bridged tropane alkaloids).

1.2 Structural class and chemistry

Tropisetron is a tropane alkaloid analog distinguished by an indole-3-carboxylate ester at the 3-position of the tropine bridge. The structural class places it within the tropeine family (3-substituted tropanes), a small group of receptor ligands that includes the strychnine-sensitive glycine receptor modulators studied by Maksay et al. and the original 5-HT₃ antagonist scaffolds [2].

Molecular formula: C₁₇H₂₀N₂O₂ (free base); C₁₇H₂₁ClN₂O₂ (hydrochloride).

Exact mass: 284.1525 g/mol (free base, monoisotopic).

Molecular weight: 284.36 g/mol (free base); 320.82 g/mol (hydrochloride salt).

Physical properties: White to off-white crystalline powder. Soluble in water (as the hydrochloride salt), methanol, and ethanol; sparingly soluble in apolar organic solvents. Melting point of the hydrochloride salt is approximately 222 to 224 degrees Celsius with decomposition. Optical rotation values for the (1R,5S)-form are reported in the European Pharmacopoeia monograph.

Stereochemistry: Tropisetron contains two stereocenters at carbons 1 and 5 of the tropane bridge and is supplied as the single (1R,5S) enantiomer. The corresponding (1S,5R) enantiomer (formally beta-tropisetron) is a research compound but is not the marketed material; it has been used in stereoselectivity studies of 5-HT₃ receptor antagonism and in glycine receptor allosteric pharmacology. Investigators acquiring research-grade tropisetron should confirm enantiomeric purity by chiral high-performance liquid chromatography or by polarimetry against a reference standard.

1.3 Synthesis

The published synthesis of tropisetron proceeds in three principal stages: preparation of indole-3-carboxylic acid (or activation of a commercial source); preparation of the tropine alcohol from tropinone (sodium borohydride reduction yields a mixture of tropine and pseudotropine, separated by recrystallization or by chromatography); and carbodiimide-mediated esterification of the tropine 3- α -hydroxyl with the activated indole carboxylic acid [3]. Carbodiimide reagents (1,3-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) with 4-dimethylaminopyridine catalysis are the standard activating system. The product is purified by recrystallization, typically from ethanol, isopropanol, or ethyl acetate, and characterized by nuclear magnetic resonance spectroscopy, melting point, and high-performance liquid chromatography. The hydrochloride salt is prepared by addition of stoichiometric hydrogen chloride in dioxane or diethyl ether followed by recrystallization. Industrial syntheses optimize the carbodiimide step for yield (typically 70 to 85 percent), enantiomeric integrity, and removal of urea byproducts; the compound is generally manufactured in high optical purity (greater than 99 percent enantiomeric excess as the hydrochloride).

2. Abstract

Tropisetron (ICS 205-930) is a high-affinity, insurmountable antagonist of the 5-hydroxytryptamine type 3 (5-HT₃) receptor and a potent, selective partial agonist of the alpha-7 subtype of the neuronal nicotinic acetylcholine receptor (alpha-7 nAChR), characteristics first formally separated in the Macor et al. (2001) report on the heterologously expressed *Xenopus* oocyte alpha-7 channel and subsequently confirmed in mouse, rat, and human systems [1]. The dual mechanism distinguishes the compound from the other clinically marketed setrons (ondansetron, granisetron, palonosetron, dolasetron, ramosetron) and underwrites a research literature that extends substantially beyond the antiemetic indication for which the compound was developed and registered.

The principal antiemetic application is the prophylaxis and treatment of acute and delayed chemotherapy-induced nausea and vomiting (CINV) at oral doses of 5 mg once daily, registered in approximately 50 jurisdictions outside the United States. The 5-HT₃ antagonist mechanism produces near-complete suppression of acute CINV in patients receiving moderately and highly emetogenic chemotherapy regimens; published comparative trials place the efficacy of tropisetron broadly equivalent to ondansetron and granisetron at registered doses, with a marginally longer duration of effect attributable to the insurmountable receptor binding and the contribution from CYP2D6 pharmacokinetics. The compound has not been approved by the United States Food and Drug Administration, and the principal antiemetic class in the United States is therefore granisetron and ondansetron.

A second clinical application, registered in some European markets and supported by a 418-patient German Fibromyalgia Study Group multicenter trial, is fibromyalgia analgesia [4, 5]. At an oral dose of 5 mg daily for 10 days, tropisetron produced a 39.2 percent response rate (defined as a 35 percent reduction in pain intensity on a visual analog scale) versus 26.2 percent on placebo. Effect was preserved on extension to 28 days. Intravenous administration at 2 mg daily for 5 days produced pain reduction in 23 of 24 fibromyalgia patients in an open-label cohort, with effect persisting 2 weeks to 2 months after the infusion course concluded [6, 7].

The third research application, undeveloped but with strong preclinical support, is cognition. The Hashimoto laboratory characterized tropisetron as ameliorating phencyclidine-induced cognitive deficits in mice through alpha-7 nicotinic mechanisms [8] and demonstrated rescue of P50 auditory gating dysfunction in DBA/2 mice [9]. Two clinical trials have extended these findings to schizophrenia patients, with short-term tropisetron treatment producing significant improvement on cognitive testing batteries and on P50 gating biomarkers [10, 11]. The Spilman et al. (2014) study identified a third target (the ectodomain of amyloid precursor protein, Kd approximately 0.9 micromolar) and reported that tropisetron at 0.5 mg/kg/day in J20 transgenic mice (a human-equivalent dose of approximately 5 mg/day) normalized spatial and working memory; effect was preserved in both pre-plaque and late-plaque disease phases [12, 13].

Pharmacokinetics are dominated by hepatic cytochrome P450 2D6 (CYP2D6) ring-hydroxylation, producing a striking polymorphic phenotype: extensive metabolizers exhibit a plasma elimination half-life of 5 to 8 hours and oral bioavailability of approximately 60 percent at 5 mg, whereas poor metabolizers (approximately 5 to 10 percent of European-ancestry populations and lower frequencies in East Asian populations) show a half-life of 30 to 40 hours and substantially elevated plasma concentrations on chronic dosing [14, 15]. Investigators conducting research with tropisetron should consider CYP2D6 phenotype as a determinant of dose-response and adverse-event interpretation.

The compound is well tolerated at registered doses. The principal short-term adverse events are constipation, headache, and dizziness, with the constipation reflecting peripheral 5-HT₃ receptor antagonism in enteric neurons. Rare arrhythmias (QT interval prolongation, supraventricular tachycardia) have been reported in postmarketing surveillance. The compound is contraindicated in patients with known CYP2D6 polymorphism and concurrent serotonin reuptake inhibitor therapy without dose adjustment.

This monograph documents chemistry, synthesis, dual-receptor pharmacology, comprehensive pharmacokinetics, the clinical evidence base across all studied indications, sourcing and quality verification considerations, reconstitution and handling, stack-interaction implications, adverse-event signal, and a structured comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates (encenicline, bradanicline, AVL-3288, GTS-21, PHA-543613) against tropisetron on five standards: novelty, effect size, promising potential, side-effect profile, and overall validation.

3. Discovery and Development History

3.1 Origin

Tropisetron (ICS 205-930) was synthesized at the Sandoz Forschungsinstitut in Vienna in the early 1980s as part of a structure-activity exploration of tropeine ligands for the then-uncharacterized 5-HT₃ receptor. The compound was selected from this series for development on the basis of high affinity (low nanomolar K_i), insurmountable antagonism, oral bioavailability, and tolerability in early animal toxicology studies. Sandoz advanced tropisetron through preclinical safety studies and Phase 1 healthy volunteer pharmacokinetic studies in the mid-1980s and through Phase 3 clinical trials for the prophylaxis of chemotherapy-induced nausea and vomiting in the late 1980s.

3.2 Antiemetic registration

Tropisetron received its first approval in the United Kingdom in 1992 and was subsequently registered in other European Union member states, in the European Free Trade Association countries, in Australia, in New Zealand, in Japan, in the Republic of Korea, in the Philippines, and in selected Latin American jurisdictions. Approved indications across these jurisdictions include prophylaxis of acute and delayed chemotherapy-induced nausea and vomiting, prophylaxis of postoperative nausea and vomiting, and (in some European markets) the analgesic indication for fibromyalgia. The original development sponsor was Sandoz, which became Novartis on the 1996 merger; the product was marketed as Navoban under Novartis ownership and is now in extensive generic competition in essentially all marketed jurisdictions. The compound has not been approved by the United States Food and Drug Administration; the historical reason was the late timing of submission relative to the early entrants ondansetron (FDA-approved 1991) and granisetron (1993) and the absence of a clear differentiating clinical claim that would have warranted independent registration.

3.3 Identification of alpha-7 nicotinic activity

The Macor et al. (2001) report from a SmithKline Beecham (now GlaxoSmithKline) and Pharmacia (now Pfizer) collaborative team formally separated the tropisetron pharmacology from the simpler 5-HT₃ antagonist class by demonstrating potent partial agonism at the homomeric alpha-7 nicotinic acetylcholine receptor in heterologously expressed *Xenopus* oocyte channels [1]. The *K_i* for displacement of [125I]-alpha-bungarotoxin from rat brain alpha-7 sites was 6.9 nanomolar (compared to ondansetron at greater than 30 micromolar). Macor et al. interpreted these findings as a basis for repositioning tropisetron and structurally related setrons as cognitive enhancement candidates and as a starting point for tropisetron-derived alpha-7 agonist medicinal chemistry programs.

3.4 Subsequent expansion of the research literature

Beginning in 2005, the Hashimoto laboratory at Chiba University extended the alpha-7 characterization to behavioral models. The seminal demonstrations were that tropisetron (subchronic administration, 0.3 to 3 mg/kg intraperitoneal) reversed phencyclidine-induced cognitive deficits in mouse novel object recognition and Morris water maze paradigms [8] and rescued the P50 auditory evoked potential suppression deficit in DBA/2 mice [9], a phenotype that models the sensory gating dysfunction observed in schizophrenia and that depends on alpha-7 nicotinic receptor function.

Two clinical trials at Chiba and at the University of Colorado extended this research-clinical bridge. Shiina et al. (2010) reported a randomized, double-blind, placebo-controlled trial of tropisetron in schizophrenia with cognitive endpoints and P50 gating measurements; tropisetron at 10 mg daily for 10 days produced significant improvement on multiple cognitive and biomarker measures compared to placebo [10]. Zhang et al. (2012) extended these findings in a larger cohort with more granular cognitive testing [11]. Both trials reported tolerability comparable to placebo at the studied doses.

The Spilman et al. (2014) report from the Bredesen laboratory at the Buck Institute identified a third target for tropisetron (the ectodomain of amyloid precursor protein) on the basis of a clinical-compound-library screen for compounds that elevated soluble amyloid precursor protein alpha (sAPPalpha) in CHO cells stably expressing wild-type human APP [12]. Tropisetron bound the APP ectodomain with a dissociation constant of approximately 0.9 micromolar (within an order of magni-

tude of its alpha-7 nicotinic functional concentrations). In the J20 transgenic mouse model of familial Alzheimer's disease, tropisetron at 0.5 mg/kg/day (corresponding to a human-equivalent oral dose of approximately 5 mg/day, the registered antiemetic and fibromyalgia dose) increased the sAPPalpha-to-amyloid-beta ratio and normalized spatial and working memory both in the pre-plaque (5 to 6 month) and late-plaque (14 month) disease phases. Performance was superior to memantine and donepezil in the same animals at clinically translatable doses.

These findings drove preparation of an investigator-initiated clinical trial of tropisetron in mild cognitive impairment and Alzheimer's disease beginning approximately 2014 [13]. The trial program has not produced a positive Phase 3 read-out as of the most recent monograph revision; the compound is not in active commercial development for cognitive indications. The current research-clinical state therefore is one of strong preclinical and biomarker support, modest small-cohort clinical evidence, and absent late-phase cognitive registration data.

4. Mechanism of Action

Tropisetron is a multi-target ligand. Its principal molecular activities, characterized in heterologous expression systems and confirmed in native tissue and behavioral models, are antagonism of the 5-HT₃ ligand-gated cation channel; partial agonism at the α -7 subtype of the neuronal nicotinic acetylcholine receptor; and a third, more recently characterized binding event at the ectodomain of amyloid precursor protein. These activities operate at functionally relevant concentrations achieved by the registered oral dose and contribute differentially to the observed antiemetic, analgesic, cognitive, and anti-inflammatory effects.

4.1 5-HT₃ receptor antagonism

The 5-HT₃ receptor is a homopentameric or heteropentameric ligand-gated cation channel of the Cys-loop superfamily, composed of five subunits (5-HT_{3A}, 5-HT_{3B}, 5-HT_{3C}, 5-HT_{3D}, 5-HT_{3E} in the various assemblies). It is expressed at high density on enteric neurons of the gastrointestinal tract, on vagal afferents projecting to the area postrema, on the area postrema itself (the chemoreceptor trigger zone), on multiple peripheral sensory neuron populations, and at lower density throughout the central nervous system including in the limbic system and the dorsal raphe.

Tropisetron binds the 5-HT_{3A} subunit (and subunit-containing assemblies) with low-nanomolar affinity. The binding is insurmountable: dissociation kinetics are slow, and increasing the agonist (serotonin) concentration does not restore channel current to baseline. The functional consequence is sustained antagonism that outlasts the plasma residence of the drug. Selectivity for 5-HT₃ over the other monoamine receptors (5-HT₁, 5-HT₂, dopamine D₁ to D₅, α -1 and α -2 adrenergic, histamine H₁) is approximately 1000-fold or greater, placing tropisetron in the high-selectivity stratum of the marketed setron class [16, 17].

The principal therapeutic consequence of 5-HT₃ antagonism is the suppression of serotonin-driven emesis. Chemotherapy-induced enterochromaffin cell degranulation releases serotonin into the gastrointestinal mucosa; serotonin acts on vagal 5-HT₃ receptors and on the area postrema to trigger emesis. Tropisetron blocks

both nodes. The peripheral 5-HT₃ antagonism additionally produces dose-dependent constipation through reduction of colonic motility and is the principal source of the reproducible mild gastrointestinal adverse-event signal in chronic dosing.

A second therapeutic consequence is analgesia. The 5-HT₃ receptor is expressed on dorsal horn nociceptive interneurons and on peripheral sensory afferents; serotonergic descending fibers from the rostral ventromedial medulla can be both pro- and anti-nociceptive depending on context, with the 5-HT₃ receptor implicated in pro-nociceptive transmission in chronic and central-sensitization pain states such as fibromyalgia [18]. Antagonism reduces dorsal horn excitability and is the principal mechanism advanced for the analgesic activity in fibromyalgia and chronic low back pain.

4.2 Alpha-7 nicotinic acetylcholine receptor partial agonism

The alpha-7 nicotinic acetylcholine receptor is a homopentameric ligand-gated cation channel of the Cys-loop superfamily (the same superfamily as 5-HT₃, GABA_A, and the strychnine-sensitive glycine receptor). It is expressed at high density on cortical and hippocampal interneurons, on basal forebrain cholinergic neurons, on hippocampal pyramidal cells, and on the cell surfaces of macrophages, T cells, and other immune cells where it mediates the cholinergic anti-inflammatory pathway. The receptor is distinguished from the heteromeric alpha-4-beta-2 nicotinic class by its rapid desensitization kinetics, its high calcium permeability (calcium-to-sodium permeability ratio approximately 20), and its selective antagonism by alpha-bungarotoxin and methyllycaconitine.

Tropisetron binds the alpha-7 nicotinic receptor at the orthosteric (acetylcholine-binding) site with a K_i of approximately 6.9 nanomolar against [125I]-alpha-bungarotoxin in rat brain membranes [1]. Functionally, in *Xenopus* oocyte and HEK293 expression systems, tropisetron acts as a partial agonist with intrinsic activity of approximately 25 to 40 percent of the maximum acetylcholine response. The functional EC₅₀ is in the low-micromolar range, reflecting the canonical concentration-effect divergence between equilibrium binding and channel activation observed at this rapidly desensitizing receptor. At lower (sub-EC₅₀) concentrations, tropisetron produces predominantly desensitization rather than activation; at con-

centrations approximating the EC50, activation predominates and is sustained for longer than the brief acetylcholine-induced burst owing to slower tropisetron dissociation.

A separate report by Callahan et al. (2017) characterized tropisetron as sensitizing alpha-7 nicotinic receptors to low concentrations of acetylcholine in vitro and as improving memory-related task performance in young and aged animals through this sensitization mechanism [19]. The cognitive enhancement profile in vivo is therefore plausibly a composite of direct partial agonism at the alpha-7 receptor and a positive allosteric or sensitizing modulatory contribution, with the pattern depending on local acetylcholine concentration.

The downstream consequences of alpha-7 nicotinic activation in cortex and hippocampus include calcium-dependent activation of calcium/calmodulin-dependent protein kinase II, ERK1/2 mitogen-activated protein kinase pathway activation, increased expression of brain-derived neurotrophic factor and nerve growth factor, and modulation of glutamate release from presynaptic terminals. These second-messenger and transcriptional consequences are the molecular basis for the procognitive activity observed in rodent behavioral models and the basis of the rationale for human cognitive trials.

The cholinergic anti-inflammatory pathway is the second principal alpha-7 nicotinic mechanism. Activation of alpha-7 nicotinic receptors on macrophages suppresses NF-kappaB-driven proinflammatory cytokine release, including tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6 [20]. The anti-inflammatory mechanism is the basis for the reported activity of tropisetron in models of sepsis, postoperative inflammation, ocular inflammation, and chronic pain, and is the molecular bridge between the receptor pharmacology and the analgesic profile in fibromyalgia.

4.3 Amyloid precursor protein ectodomain binding

The Spilman et al. (2014) screen identified tropisetron as an elevator of soluble amyloid precursor protein alpha (sAPPalpha) in Chinese hamster ovary cells stably expressing wild-type human APP [12]. The mechanism was characterized by direct binding to the APP ectodomain at a site distinct from the alpha-secretase cleavage product, with a dissociation constant of approximately 0.9 micromolar. The binding promoted alpha-secretase processing of APP (which produces the neurotrophic sAPPalpha) and avoids the amyloidogenic beta-secretase pathway that produces

amyloid-beta). The molecular basis of the binding site (which subdomain of the APP ectodomain, what affinity the sequence-related fragment, what implications for paralogs APLP1 and APLP2) has not been fully elucidated and is a subject of ongoing investigation.

The therapeutic consequence in J20 transgenic mice (which express the Swedish and Indiana mutations in human APP and develop amyloid plaques and cognitive deficits) was normalization of spatial memory and working memory at a clinically translatable oral dose of 0.5 mg/kg/day, translating by interspecies allometric scaling to approximately 5 mg/day in humans (the registered antiemetic and fibromyalgia dose). The improvement was reported across both the pre-plaque (5 to 6 month) and late-plaque (14 month) phases of the disease and was greater in magnitude than the comparator-arm donepezil and memantine in the same study at their clinical-equivalent doses [12].

The composite dual-receptor and tertiary-binding mechanism of tropisetron is therefore a strong substrate for the diverse research-clinical applications observed across the spectrum of indications, and a partial mechanistic basis for cognitive enhancement, anti-inflammatory effects, and analgesia that are not predictable from 5-HT₃ antagonism alone.

4.4 Composite pharmacology and selectivity

The composite pharmacology of tropisetron at the registered 5 mg oral dose produces approximate plasma free concentrations of 5 to 10 nanomolar at peak (extensive metabolizers). At this concentration, near-complete 5-HT₃ receptor antagonism is achieved (K_i approximately 0.5 to 5 nM, plasma free concentrations exceeding the K_i by 1 to 2 orders of magnitude); functional α -7 nicotinic partial agonism is borderline (EC_{50} approximately 1 to 10 micromolar, plasma free concentrations 100 to 1000-fold below this); and APP ectodomain binding (K_d approximately 0.9 micromolar) is similarly borderline.

The clinical implication is that the antiemetic effect at registered doses is predominantly 5-HT₃ antagonism, while the cognitive, anti-inflammatory, and APP-mediated effects are likely supported by a combination of (a) partial occupancy of α -7 nicotinic receptors at physiologically meaningful levels (especially given the slow dissociation kinetics and the contribution from accumulated drug in CYP2D6 poor metabolizers); (b) accumulation in the central nervous system with chronic dosing; and (c) the composite of α -7 sensitization and APP binding as a

tertiary mechanism. Higher doses (10 to 25 mg) studied in some research-clinical applications would predict approximately proportional increases in plasma concentration and therefore approximately linear dose-response on the alpha-7 and APP targets.

A positron emission tomography study of [11C]-CHIBA-1001 binding in healthy human brain reported that tropisetron produced demonstrable receptor occupancy at the alpha-7 nicotinic receptor at clinical doses, supporting the in vivo translation of the in vitro pharmacology [21].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Tropisetron is well absorbed from the gastrointestinal tract after oral administration. Bioavailability is approximately 60 percent at a 5 mg oral dose in extensive CYP2D6 metabolizers and approaches 100 percent in poor metabolizers, the difference attributable to the magnitude of first-pass hepatic CYP2D6-mediated metabolism [14, 15]. Time to peak plasma concentration after oral administration is approximately 2.5 to 3 hours in extensive metabolizers, with food modestly delaying absorption without affecting overall exposure. Maximum plasma concentration after a 5 mg oral dose in fasted extensive metabolizers is approximately 3.5 nanograms per milliliter (12 nanomolar) [14].

Intravenous tropisetron at a 5 mg dose produces immediate peak plasma concentrations on the order of 50 to 60 nanograms per milliliter, with concentration returning to oral peak levels within approximately 30 minutes by central compartment redistribution.

5.2 Distribution

Tropisetron has substantial volume of distribution (approximately 5 to 6 liters per kilogram), reflecting moderate tissue partitioning. Plasma protein binding is approximately 71 percent, predominantly to albumin and alpha-1-acid glycoprotein. The compound crosses the blood-brain barrier; central nervous system penetration is moderate, supporting central effects on vagal afferent processing and on central nicotinic-cholinergic targets. The compound is a substrate of P-glycoprotein in some assays but is not strongly effluxed at clinical concentrations; central nervous system exposure in humans has been characterized by [11C]-CHIBA-1001 positron emission tomography demonstrating frontal and temporal cortex distribution consistent with alpha-7 nicotinic receptor density [21].

5.3 Metabolism

Tropisetron is metabolized predominantly in the liver by cytochrome P450 enzymes. The principal metabolic transformation is ring hydroxylation at the 5-, 6-, or 7-position of the indole ring, producing inactive hydroxylated metabolites that are subsequently glucuronidated and excreted in urine. The dominant CYP isoform responsible for the ring hydroxylation is CYP2D6, with smaller contributions from CYP3A4 [22, 23].

The CYP2D6 dependence is the source of the most clinically and pharmacologically important pharmacokinetic feature of tropisetron: a striking polymorphic phenotype. The CYP2D6 gene carries multiple loss-of-function alleles (CYP2D6 *3, *4, *5, *6, *7, *8, *11, *12, *14, *15, *36, *38, *40, *41 and others) that segregate at varying frequency across global populations. Individuals carrying two loss-of-function alleles ("poor metabolizers") have essentially absent CYP2D6 activity and metabolize tropisetron predominantly through CYP3A4 and other minor pathways. The phenotypic distribution is approximately 5 to 10 percent poor metabolizer in European-ancestry populations, approximately 1 to 2 percent in East Asian populations, and approximately 2 to 5 percent in sub-Saharan African populations.

Plasma elimination half-life for tropisetron in CYP2D6 extensive metabolizers (the majority phenotype) is 5 to 8 hours after oral dosing and approximately 5.6 hours after intravenous dosing [14]. In CYP2D6 poor metabolizers, the elimination half-life extends to 30 to 40 hours, and steady-state plasma concentrations on chronic 5 mg daily dosing are approximately 5- to 10-fold higher than in extensive metabolizers [15].

The Kim et al. (2003) study in Korean subjects with characterized CYP2D6 genotypes confirmed and quantified this phenotype: extensive metabolizers (CYP2D6 *1/*1) showed the expected pharmacokinetic profile, while subjects carrying loss-of-function alleles (predominantly *10, the East Asian variant with reduced enzyme activity) showed substantially elevated AUC and prolonged half-life on the same dose [15].

The clinical implication is that dose adjustment in known CYP2D6 poor metabolizers is appropriate, and that the increased plasma concentration in these individuals likely accounts for some of the heterogeneity in adverse-event rates observed in registration trials. Drug-drug interactions with strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) substantially increase tropisetron exposure and should be considered in concurrent prescribing.

5.4 Elimination

Renal excretion is the principal elimination pathway for the conjugated metabolites; less than 10 percent of an administered dose is excreted unchanged in urine. Biliary excretion accounts for a minor fraction. The elimination is therefore predominantly metabolic (CYP2D6-mediated hepatic biotransformation) rather than direct renal clearance.

Renal impairment has minimal effect on tropisetron pharmacokinetics; hepatic impairment can substantially prolong elimination, particularly in conjunction with CYP2D6 polymorphism, and dose adjustment in severe hepatic impairment is recommended in some prescribing labels.

5.5 Routes of administration

Three principal routes are used clinically and in research: oral (5 mg daily, registered antiemetic and fibromyalgia indication), intravenous bolus (5 mg in 5 milliliters over 30 to 60 seconds, registered for pre-chemotherapy or immediate postoperative antiemesis), and intravenous infusion (typically 5 mg in 100 milliliters of normal saline over 15 to 30 minutes). Intramuscular and subcutaneous administration have been used in research but are not registered. The compound is stable in solution at refrigerated conditions for 14 to 30 days after reconstitution (consistent with the bacteriostatic water reconstitution profile of pharmaceutical-grade peptides).

5.6 Special populations

Pediatric pharmacokinetics have been characterized. The compound is approved for pediatric use in some jurisdictions for chemotherapy-induced nausea and vomiting at body-weight-adjusted doses (typically 0.2 mg/kg). Geriatric pharmacokinetics are similar to adult except in the context of CYP2D6 phenotype and concurrent strong CYP2D6 inhibitor exposure. Pregnancy data are limited; the compound is rated category B in some jurisdictions (no human data, no animal teratogenicity at multiples of human dose). Use in lactation is discouraged owing to limited data.

6. Clinical Evidence Base

6.1 Antiemetic indications

The antiemetic indication is the principal registered application of tropisetron. Acute and delayed chemotherapy-induced nausea and vomiting (CINV) prophylaxis at oral 5 mg daily produces near-complete control of acute emesis (greater than 70 percent control rate) in patients receiving moderately and highly emetogenic chemotherapy, similar to ondansetron (8 mg twice daily) and granisetron (1 mg daily) at registered doses [24]. The control rate for delayed emesis (24 to 96 hours post-chemotherapy) is similar at approximately 55 to 65 percent. Comparative trials place tropisetron broadly equivalent to the comparator setrons.

Postoperative nausea and vomiting (PONV) prophylaxis at intravenous 2 mg or 5 mg pre-induction produces similar control rates to ondansetron 4 mg in published comparative trials.

6.2 Fibromyalgia and chronic pain

The German Fibromyalgia Study Group multicenter randomized double-blind placebo-controlled trial of tropisetron in 418 fibromyalgia patients (Färber et al. 2001) is the principal registration trial in this indication [4]. Patients were randomized to placebo, 5 mg, 10 mg, or 15 mg of tropisetron once daily for 10 days. The 5 mg dose produced a 39.2 percent response rate (defined as 35 percent or greater reduction in pain intensity on a visual analog scale) compared to 26.2 percent on placebo, a statistically significant difference. Higher doses (10 mg and 15 mg) did not produce greater response rates, suggesting an inverted-U dose-response relationship characteristic of dual-mechanism agents and consistent with the alpha-7 nicotinic partial agonist contribution.

The Späth et al. (2001) and Müller and Stratz (2004) follow-up studies extended efficacy through 28-day continuous oral dosing and 5-day intravenous courses, with effect persisting weeks to months after the dosing course concluded [5, 6]. The intravenous protocol (2 mg daily for 5 days) produced 95 percent response rates with

effect maintained for 2 weeks to 2 months, suggesting that disease-modifying central anti-inflammatory and alpha-7 nicotinic mechanisms contribute to the clinical effect beyond simple analgesic blockade [7].

The Neziri et al. (2012) study extended the analgesic profile to chronic low back pain with central sensitization features [25]. Intravenous tropisetron acutely reduced electrical and mechanical pain thresholds and reduced spontaneous pain scores in a cohort of chronic low back pain patients, supporting the mechanism-based extension to broader chronic pain syndromes.

6.3 Cognitive endpoints in schizophrenia

Two clinical trials have formally evaluated tropisetron in schizophrenia cognitive endpoints. The Shiina et al. (2010) randomized double-blind placebo-controlled trial in 40 schizophrenia patients reported significant improvement on cognitive battery measures (digit symbol substitution, trail-making, and verbal fluency) and on P50 auditory evoked potential gating after 10 days of tropisetron 5 mg daily [10]. The Zhang et al. (2012) report in the American Journal of Psychiatry replicated the cognitive improvement at the same dose in a 4-week study and extended the P50 gating biomarker observations [11].

A follow-up report by Wang et al. (2020) found that one-day tropisetron treatment was sufficient to demonstrate significant improvement on cognitive deficits and P50 inhibition, suggesting that the procognitive effect is acute and not solely accumulating with chronic dosing [26]. The acute effect supports a direct central nervous system mechanism (alpha-7 nicotinic and APP-mediated) rather than chronic neuroplastic remodeling.

6.4 Alzheimer's disease

The Spilman et al. (2014) preclinical demonstration in J20 transgenic mice was the basis for an investigator-initiated clinical trial of tropisetron in mild cognitive impairment and early Alzheimer's disease beginning approximately 2014 [12, 13]. The trial was reportedly conducted at the Buck Institute and at affiliated sites; results have not been published in a peer-reviewed forum as of the most recent monograph revision, and the compound is not in active commercial development for

cognitive indications. The current research-clinical state therefore is one of strong preclinical and biomarker support, modest small-cohort schizophrenia clinical evidence, and absent late-phase Alzheimer's registration data.

6.5 Tinnitus

Tropisetron has been studied for chronic tinnitus on the basis of the 5-HT₃ antagonist mechanism (modulating central auditory processing) and the alpha-7 nicotinic anti-inflammatory mechanism. Clinical evidence is limited; the compound is not registered for this indication and has not produced replicable benefit in randomized trials. The research-clinical literature on serotonergic antagonist pharmacology in tinnitus is broadly negative, with effective interventions in chronic primary tinnitus dominated by sound therapy, cognitive behavioral therapy, and selected pharmacotherapies (lidocaine bolus, gabapentin, low-dose tricyclic antidepressants).

6.6 Inflammatory conditions

Tropisetron has been characterized in animal and human research as anti-inflammatory through alpha-7 nicotinic activation of the cholinergic anti-inflammatory pathway. Reported applications include sepsis, acute lung injury, rheumatoid arthritis, ocular inflammation, and pruritus [20]. Clinical evidence in any of these indications is limited and comprises principally case series and small open-label studies; none of the inflammatory indications has produced a registration trial. The mechanism is plausible and is supported by preclinical work; the clinical translation has not produced an established second indication.

7. Reported Research Dose Ranges

7.1 Approved doses

Antiemetic indication (chemotherapy-induced and postoperative nausea and vomiting): 5 mg per oral administration once daily for the duration of the antiemetic regimen, typically 5 to 7 days. Intravenous: 2 mg or 5 mg as a slow intravenous push or short infusion, immediately pre-chemotherapy or pre-induction.

Fibromyalgia indication (in jurisdictions where approved): 5 mg per oral administration once daily for 10 to 28 days, with reassessment of pain response at day 10. Intravenous protocol: 2 mg per day for 5 days as a continuous or intermittent infusion.

7.2 Investigational doses

Schizophrenia cognitive endpoints: 5 to 25 mg per oral administration once daily for 10 days. Effect appears at 5 mg and is greater at 10 mg with comparable tolerability; doses above 10 mg have not produced consistent additional benefit and may approach the inverted-U dose-response observed in fibromyalgia.

Alzheimer's disease (proposed): 5 mg per oral administration once daily, the registered antiemetic dose. The Spilman et al. (2014) preclinical data and the human-equivalent dose translation supported this dose as the initial clinical candidate dose for Alzheimer's research.

Inflammatory and analgesic research: 5 to 10 mg per oral administration once daily, or 2 to 5 mg per intravenous infusion daily for 5 to 10 days. Dose selection within this range is based on the individual study endpoint and the comparator arm.

Investigators acquiring research-grade tropisetron should treat dose ranges as starting points for their own pharmacokinetic and tolerability characterization, especially given the potential for substantial inter-individual variability driven by CYP2D6 phenotype.

8. Sourcing and Quality Verification

Pharmaceutical-grade tropisetron (Navoban brand or licensed generic) is the highest quality source for research applications where regulatory equivalence to clinical material is operationally important. The pharmaceutical-grade material is supplied as 5 mg or 25 mg oral capsules and as 2 mg or 5 mg intravenous ampoules in the marketed formulations. Pharmaceutical sourcing is feasible in jurisdictions where the compound is registered (Australia, New Zealand, Japan, several European Union member states, the Republic of Korea, the Philippines).

Research-grade tropisetron is supplied by multiple chemical and pharmaceutical research suppliers (Tocris, Sigma-Aldrich, Cayman Chemical, MedChemExpress, Selleckchem, BocSci, others) at greater than 98 percent purity by HPLC. Supply is in milligram to gram quantities as the hydrochloride salt; the free base is also available but less commonly. Pricing is moderate, in the range of \$50 to \$200 per gram of pharmaceutical-grade research material at the time of monograph preparation.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (284.15 ± 0.01 for the protonated free base $[M+H]^+$)
- Optical rotation or chiral HPLC confirmation of enantiomeric purity (greater than 99 percent enantiomeric excess of the (1R,5S) form, since the (1S,5R) enantiomer is a research compound but is not the clinically active material)
- Karl Fischer or loss-on-drying analysis for residual water
- Residual solvent analysis (gas chromatography of common synthesis solvents: methanol, ethanol, dichloromethane, ethyl acetate)

Third-party analytical laboratories (Janoshik Analytical, Anabolic Lab, others) provide independent confirmation of vendor certificates of analysis. The research-grade tropisetron market is well established and counterfeit material is uncommon.

mon, but lot-to-lot variability is observed and on-receipt analytical confirmation is appropriate for any investigation where dose-response or mechanism-of-action precision is important.

9. Reconstitution and Handling

Tropisetron hydrochloride is freely soluble in water at room temperature. For research applications, the compound is supplied as a lyophilized or crystalline powder and is reconstituted as needed. Stock solutions are typically prepared at 10 to 100 mg/mL in normal saline, in dimethyl sulfoxide for in vitro work where higher concentrations are required, or in bacteriostatic water for injection for parenteral research applications.

Refrigerated storage (2 to 8 degrees Celsius) of the solid is appropriate; the compound is stable at room temperature in dry conditions and at refrigerated conditions in solution for at least 30 days. Light protection is not required but is reasonable practice. Aqueous stock solutions should be used within 14 to 30 days of preparation (consistent with bacteriostatic water reconstitution standards) and within 24 hours of preparation for sterile water reconstitution.

Aliquoting of stock solution for single-use is recommended to avoid freeze-thaw cycles in repeated stock access; stable freeze-thaw resistance has been demonstrated to at least 5 cycles without measurable potency loss.

For clinical-research formulations, the compound is supplied as a 2 mg/mL or 5 mg/mL aqueous solution in sealed glass ampoules (the marketed Navoban presentation) and is administered as a slow intravenous push (over 30 to 60 seconds for the 2 mg or 5 mg dose) or as a short intravenous infusion (in 50 to 100 milliliters of normal saline over 15 to 30 minutes).

10. Stack Interaction Considerations

Tropisetron interacts with several drug classes through its CYP2D6-mediated metabolism and through its dual-receptor pharmacology. Investigators conducting research with tropisetron, especially in chronic dosing regimens or in combination with other research compounds, should consider:

CYP2D6 inhibitors: Strong inhibitors (paroxetine, fluoxetine, bupropion, quinidine, terbinafine) can substantially elevate tropisetron exposure. Concurrent use should be considered for dose reduction. Moderate inhibitors (sertraline, escitalopram, duloxetine) produce smaller but measurable effects. Investigators with research participants on chronic SSRI therapy should consider both the CYP2D6 interaction and the additive serotonergic considerations.

CYP2D6 inducers: Inducers (rifampin, carbamazepine, phenytoin) reduce tropisetron exposure. Concurrent dosing reduces the effective tropisetron concentration and may compromise efficacy in dose-response research.

Other 5-HT₃ antagonists: Concurrent use with another setron is pharmacologically redundant for the 5-HT₃ antagonist effect and may produce additive QT-prolongation risk. The combination is not recommended in clinical practice and is rare in research.

Other alpha-7 nicotinic agonists or PAMs: Concurrent administration with other alpha-7 nicotinic candidates (encenicline, bradanicline, AVL-3288, GTS-21) produces additive effects on the alpha-7 receptor and may exceed the desensitization threshold above which the receptor enters extended low-conductance states. The combination has not been studied in research-clinical contexts but may be a productive line of investigation for fundamental alpha-7 receptor pharmacology and is unlikely to be clinically translatable.

QT-prolonging agents: Tropisetron has produced rare clinically significant QT interval prolongation in postmarketing surveillance. Combination with other QT-prolonging agents (other setrons, methadone, fluoroquinolones, high-dose haloperidol, citalopram, escitalopram) increases the risk and should be approached with caution.

Cholinergic agents: Concurrent acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine, pyridostigmine) produce additive cholinergic activity; the combination is plausible for cognitive research applications but additive parasympathomimetic adverse-event signal should be expected.

Centrally acting analgesics: Concurrent opioids and tropisetron have been used in the postoperative setting; the 5-HT₃ antagonist mechanism may modestly reduce opioid-induced nausea but does not produce additive analgesia. Concurrent gabapentin, pregabalin, or low-dose tricyclic antidepressants for chronic pain produce no characterized PK interaction but may produce additive sedative or anticholinergic effects.

11. Adverse Events and Safety

11.1 Common adverse events

The principal adverse events at registered doses are:

- Constipation (10 to 15 percent at 5 mg daily, dose-dependent; reflects peripheral 5-HT₃ antagonism in enteric neurons)
- Headache (5 to 10 percent)
- Dizziness (3 to 5 percent)
- Fatigue (2 to 4 percent)
- Hypertension (transient, 1 to 3 percent, principally at intravenous doses; mechanism unclear, possibly related to acute 5-HT₃ receptor antagonism on sympathetic postganglionic neurons)

These adverse-event rates are similar to or modestly lower than the comparator setrons and are consistent across the registered antiemetic and analgesic indications. The constipation can be managed with osmotic laxatives or short-duration fiber supplementation in chronic dosing.

11.2 Rare and serious adverse events

Postmarketing surveillance has identified rare clinically significant events:

- QT interval prolongation, with rare torsade de pointes in individuals with predisposing factors (pre-existing QT prolongation, electrolyte abnormalities, concurrent QT-prolonging medications). The compound has been associated with this signal as a class effect of the setrons.
- Severe constipation with bowel obstruction in individual cases, principally in the elderly with comorbid conditions
- Hypersensitivity reactions including anaphylaxis (rare, in the order of 1 in 100,000 administrations)
- Hepatic enzyme elevation (rare, generally clinically insignificant)
- Extrapyrarnidal symptoms in rare cases at higher than registered doses

11.3 CYP2D6 considerations

The CYP2D6 polymorphism is the principal pharmacokinetic risk factor for adverse events. Poor metabolizers experience approximately 5- to 10-fold higher steady-state plasma concentrations on chronic dosing and consequently a higher rate of adverse events. Investigators with research participants whose CYP2D6 status is unknown should consider the implications of elevated exposure for adverse-event interpretation.

11.4 Pregnancy and lactation

Pregnancy data in humans are limited. Animal teratogenicity studies have not demonstrated developmental toxicity at multiples of the human dose. The compound is rated FDA pregnancy category B in some jurisdictions, indicating absence of human data with absence of animal evidence of harm. Use in pregnancy is generally discouraged unless clearly indicated. Lactation data are limited; the compound is excreted in human milk in trace amounts.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates against tropisetron, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile (clinical or in vitro), and overall validation. The five candidates were selected as the principal alpha-7 nicotinic ligands with substantive clinical or preclinical pharmacology programs in cognitive applications, with priority on those that have produced material clinical evidence and on those that share Tropisetron's research-clinical positioning.

The comparison is constructed to inform research-application decisions and to clarify the scientific positioning of tropisetron in the broader alpha-7 nicotinic receptor pharmacology space.

12.1 Encenicline (EVP-6124, MT-4666)

Mechanism: Selective alpha-7 nicotinic acetylcholine receptor partial agonist. Functional intrinsic activity in heterologous expression systems is approximately 60 to 70 percent of acetylcholine maximum, higher than tropisetron at the same receptor.

Development trajectory: EnVivo Pharmaceuticals (later Forum Pharmaceuticals) advanced encenicline through extensive Phase 2 trials in schizophrenia cognitive impairment and in Alzheimer's disease, with Phase 1/2 data published by Maelicke et al. (2014) showing safety and tolerability in 49 subjects with mild to moderate Alzheimer's disease at doses of 0.1 to 1 mg/day for 28 days [27]. A larger Phase 2 study in 319 schizophrenia patients (Keefe et al. 2015) reported significant cognitive improvement on the Overall Cognition Index at 0.27 mg and 0.9 mg doses [28]. Forum advanced the compound to two global Phase 3 schizophrenia studies (COGNITIV-CIAS-1 and COGNITIV-CIAS-2) and an Alzheimer's disease Phase 3 program (COGNITIV-AD).

Clinical outcome: In September 2015, the FDA placed a clinical hold on the Phase 3 programs following reports of severe gastrointestinal adverse events (severe nausea, vomiting, ulceration) in a small subset of patients [29]. The hold was partially lifted in November 2015 to permit completion of the Phase 3 trials. In March 2016, Forum announced that both Phase 3 schizophrenia trials had missed their co-primary endpoints; the program was discontinued and the company was wound down. The clinical trajectory therefore terminates at Phase 3 negative readouts, despite Phase 2 cognitive efficacy signals.

Novelty: Moderate. The alpha-7 nicotinic partial agonist mechanism is non-novel within the broader class but encenicline represented a more selective, more potent variant than tropisetron at the time of development.

Effect size: Phase 2 schizophrenia trials reported Cohen's d effect sizes on cognitive composite of approximately 0.3 to 0.5, consistent with a small-to-moderate cognitive enhancement [28]. The Phase 3 effect size was insufficient to meet the registration endpoint.

Promising potential: Low. Development is terminated. The compound is no longer in active commercial development and is not available as a registered medicine. Research-grade encenicline is available from chemical suppliers for in vitro and in vivo work; the compound serves as a reference alpha-7 nicotinic partial agonist for fundamental pharmacology research.

Side-effect profile: The principal safety concern was gastrointestinal: severe nausea, vomiting, ulceration, and gastrointestinal bleeding in a small fraction of patients (the basis for the FDA clinical hold). The mechanism of the gastrointestinal toxicity is incompletely characterized but is plausibly related to alpha-7 receptor activation in enteric neurons and on enteric immune cells. Other adverse events (headache, dizziness, fatigue) were modest and similar to placebo. The gastrointestinal signal is more pronounced than what tropisetron produces; the difference may reflect the higher intrinsic activity of encenicline at the alpha-7 receptor or the off-target activities of the compound.

Overall validation: Moderate. The compound advanced through rigorous Phase 2 development with positive cognitive endpoints but failed at Phase 3 with both negative efficacy and modest safety concerns. The clinical-pharmacology research literature on encenicline is substantial and is a useful reference for the alpha-7 nicotinic receptor partial agonist mechanism. The negative Phase 3 outcome has mate-

rially reduced enthusiasm for alpha-7 nicotinic receptor partial agonism as a single-target strategy in cognitive impairment of schizophrenia and Alzheimer's disease.

Comparison to tropisetron: Encenicline has higher selectivity and intrinsic activity at the alpha-7 nicotinic receptor than tropisetron and a substantially more developed clinical trajectory through Phase 3, though terminated. Tropisetron has the advantage of registered antiemetic and analgesic indications, an established clinical safety profile at the registered doses, and the additional mechanism of APP ectodomain binding that encenicline does not have. The tropisetron clinical trajectory in cognition is much smaller in scale than the encenicline trajectory but is more recent and is informed by the encenicline Phase 3 lessons (notably, the importance of safety monitoring and of mechanistic stratification in trial design). The two compounds are mechanistically related and complementary research tools.

12.2 Bradanicline (TC-5619)

Mechanism: Selective alpha-7 nicotinic acetylcholine receptor full agonist; binding affinity K_i approximately 1.4 nanomolar at human alpha-7 nicotinic receptor [30]. Functional intrinsic activity in heterologous expression systems is approximately 80 to 90 percent of acetylcholine maximum, higher than encenicline (60 to 70 percent) and substantially higher than tropisetron (25 to 40 percent).

Development trajectory: Targacept advanced bradanicline through Phase 2 development for schizophrenia cognitive impairment. The exploratory Phase 2 study (Lieberman et al. 2013) in 185 schizophrenia patients reported a statistically significant drug effect on the Groton Maze Learning Task and on the Scale for Assessment of Negative Symptoms over 12 weeks [30]. A larger Phase 2 study (Walling et al. 2016) in 477 schizophrenia outpatients across 64 sites randomized to placebo, 5 mg, or 50 mg of TC-5619 for 24 weeks did not support a benefit on negative or cognitive symptoms [31]. The compound was subsequently licensed to Catalyst Biosciences and to Anvylic Therapeutics for Tourette syndrome and other indications; the cognitive impairment program in schizophrenia has been deprioritized.

Novelty: Low. The mechanism is conventional alpha-7 nicotinic full agonism within a well-explored medicinal chemistry space.

Effect size: Mixed. Phase 2 exploratory study showed positive cognitive signals; larger Phase 2 study showed no benefit. The dispersion is consistent with effect-size small enough to be visible in selected subpopulations (notably tobacco users in the exploratory study) but insufficient for replication at scale.

Promising potential: Low to moderate. The compound is no longer in active development for cognitive impairment of schizophrenia. Anvylic continued development for Tourette syndrome. Research-grade bradanicline is available from chemical suppliers.

Side-effect profile: The compound was generally well tolerated in Phase 2 studies, with no clinically noteworthy safety findings reported. Gastrointestinal effects were not as severe as those that produced the encenicline FDA clinical hold; the difference is plausibly attributable to the absence of the encenicline-specific off-target activities or to dose differences.

Overall validation: Low to moderate. The compound advanced through Phase 2 with mixed efficacy results and acceptable safety. The clinical-pharmacology research literature is moderate in size.

Comparison to tropisetron: Bradanicline is a more potent and more efficacious alpha-7 nicotinic agonist than tropisetron at the receptor level. Tropisetron's effect-size in clinical schizophrenia cognitive endpoints (Shiina 2010, Zhang 2012) is broadly comparable in magnitude to the Lieberman 2013 bradanicline data, though across different cognitive batteries and at different sample sizes. Tropisetron has the operational advantage of registered antiemetic and fibromyalgia indications and an established clinical safety profile at the registered doses; bradanicline does not have a registered indication.

12.3 AVL-3288 (UCI-4083, CCMI)

Mechanism: Type I positive allosteric modulator (PAM) of the alpha-7 nicotinic acetylcholine receptor. Type I PAMs enhance receptor activation by endogenous acetylcholine without directly activating the receptor in the absence of agonist; they preserve the spatiotemporal specificity of cholinergic neurotransmission and the rapid desensitization kinetics of the alpha-7 receptor [32]. This mechanism is fundamentally different from the partial or full agonism of tropisetron, encenicline, bradanicline, and PHA-543613.

Development trajectory: A first-in-human single-dose oral ascending dose Phase 1a study in 21 healthy non-smokers (Gee et al. 2017) reported safety and tolerability at 5, 10, and 30 mg doses; pharmacokinetic profile consistent with once-daily dosing; and indications of positive but non-significant effects on neurocognition at 10 and 30 mg [32]. The compound was subsequently advanced to a Phase 1b randomized double-blind placebo-controlled triple-cross-over study in 24 non-smoking medicated outpatients with schizophrenia (Freedman et al. 2020) at 10 mg and 30 mg doses [33]. The Phase 1b study reported tolerability, P50 auditory gating biomarker effects at 30 mg, and signals on cognitive performance.

Novelty: High. The alpha-7 nicotinic receptor type I PAM mechanism is fundamentally distinct from the partial and full agonist mechanisms of the other comparators. The PAM approach preserves endogenous cholinergic signal patterning and avoids the receptor desensitization concerns that limit potent agonist development. This is a meaningfully different therapeutic concept and represents the most novel of the alpha-7 nicotinic candidates evaluated against tropisetron.

Effect size: Phase 1b cognitive signals are modest and exploratory. The compound has not been advanced to Phase 2.

Promising potential: Moderate. The novel mechanism is therapeutically attractive and the safety profile in Phase 1 has been favorable. The compound is owned by Anylyc Therapeutics and the future trajectory depends on funding for Phase 2 development. Research-grade AVL-3288 is available from chemical suppliers for fundamental pharmacology and preclinical work.

Side-effect profile: Phase 1 and Phase 1b studies have not produced material safety concerns. The PAM mechanism is theoretically expected to produce a more favorable side-effect profile than the agonist class because of the dependence on endogenous cholinergic signaling for activation, which limits non-physiological receptor activation.

Overall validation: Low to moderate. The compound has produced Phase 1b cognitive and biomarker signals in a small schizophrenia cohort. The clinical-pharmacology research literature is small but growing. The mechanistic novelty is the principal scientific basis for continued attention.

Comparison to tropisetron: AVL-3288 represents the most mechanistically distinct alpha-7 nicotinic candidate against tropisetron in this comparator panel. Tropisetron acts at the orthosteric (acetylcholine-binding) site of the alpha-7 recep-

tor as a partial agonist, whereas AVL-3288 acts at a separate allosteric site as a positive modulator. The two mechanisms could be complementary; combination research would test whether AVL-3288 modulation of endogenous acetylcholine signaling could augment the tropisetron partial agonism. Tropisetron has the operational advantage of registered indications and a substantial clinical safety database; AVL-3288 has the mechanistic advantage of a more selective and a more endogenous-signal-preserving approach to alpha-7 nicotinic receptor pharmacology.

12.4 GTS-21 (DMXBA, 3-(2,4-dimethoxybenzylidene)anabaseine)

Mechanism: Partial agonist at the alpha-7 nicotinic acetylcholine receptor; partial agonist or antagonist at the alpha-4-beta-2 nicotinic receptor depending on assay. Functional intrinsic activity at alpha-7 in heterologous expression systems is approximately 30 to 50 percent of acetylcholine maximum. The alpha-4-beta-2 binding adds a complication absent from the more selective tropisetron, encenicline, and bradanicline pharmacology.

Development trajectory: GTS-21 is a derivative of the natural anabaseine alkaloid and was advanced through Phase 1 and Phase 2 trials for cognitive applications by Comentis and by Taiho Pharmaceutical. Multiple Phase 2 trials in schizophrenia (Olincy et al. 2006, 2017), Alzheimer's disease, and healthy volunteer cognition have been completed [34]. The Olincy et al. (2017) randomized trial in 65 schizophrenia patients with extended-release formulation at 75 mg three times daily for 4 weeks did not show significant cognitive improvement on the MATRICS battery, despite earlier signals in immediate-release formulations [34]. The compound is no longer in active commercial development; research-grade GTS-21 is widely available.

Novelty: Low. The mechanism and chemistry are well established. GTS-21 is the longest-studied alpha-7 nicotinic partial agonist in cognitive applications and is the historical reference compound for the class.

Effect size: Modest in early Phase 2 immediate-release studies; non-significant in larger replicated extended-release Phase 2 studies. The pattern is consistent with a small effect that does not survive statistical scrutiny at scale.

Promising potential: Low. Development is essentially terminated for cognitive applications. The compound persists as a research tool.

Side-effect profile: Phase 1 and Phase 2 studies have demonstrated tolerability; no material safety concerns have been reported. Some non-specific gastrointestinal and central nervous system adverse events at higher doses but no severe events.

Overall validation: Moderate. The compound has produced an extensive clinical-pharmacology research literature over approximately 20 years and is the historical reference compound for the alpha-7 nicotinic partial agonist class. The effect sizes in Phase 2 have not supported registration.

Comparison to tropisetron: GTS-21 and tropisetron share the alpha-7 nicotinic partial agonist mechanism but are dissimilar in selectivity (GTS-21 has alpha-4-beta-2 cross-reactivity, tropisetron has 5-HT3 cross-reactivity and APP ectodomain binding) and in clinical trajectory (GTS-21 advanced extensively in Phase 2, tropisetron has produced only small-cohort exploratory data). Tropisetron has the advantage of registered indications; GTS-21 has the advantage of the longer clinical research history.

12.5 PHA-543613

Mechanism: Highly selective alpha-7 nicotinic acetylcholine receptor agonist with full agonist intrinsic activity in heterologous expression systems. Brain-penetrant and orally bioavailable in rodent species.

Development trajectory: Pfizer research compound. The principal published evidence is preclinical and is in rodent cognitive models. The compound has not been advanced to human clinical trials in published form; it serves as a research tool for fundamental alpha-7 nicotinic pharmacology and for combination-research applications. Significant recent work in 2024 to 2025 has demonstrated efficacy in prenilin double-knockout mouse models of Alzheimer's disease and synergistic effects with memantine in aged rats [35, 36].

Novelty: Low to moderate. The mechanism is conventional; the compound is well characterized but is not in clinical development.

Effect size: Substantial in preclinical rodent cognitive models, particularly in scopolamine-induced amnesia, in amyloid-beta-induced cognitive deficit models, and in aged-rat working memory paradigms in combination with memantine [36]. Effect sizes in animal models do not translate predictively to human clinical effect.

Promising potential: Limited as a clinical candidate (no clinical development). Substantial as a research tool for understanding alpha-7 nicotinic mechanisms in cognition and in combination-pharmacology research.

Side-effect profile: Preclinical only. No human safety data. Rodent safety has been adequate at studied doses.

Overall validation: Low. The compound is principally a research tool with no clinical validation.

Comparison to tropisetron: PHA-543613 is a more potent and more selective alpha-7 nicotinic agonist than tropisetron at the receptor level. Tropisetron has the advantages of clinical registration, a substantial human safety database, multiple complementary mechanisms (5-HT₃ antagonism, APP ectodomain binding), and an established research-clinical evidence base. PHA-543613 has the advantages of receptor selectivity and brain penetration that may favor fundamental research applications and may inform mechanism dissection, but does not currently constitute a clinical alternative.

12.6 Comparator summary

The five compounds occupy distinct positions in the alpha-7 nicotinic acetylcholine receptor pharmacology space. **Encenicline** represents the most mature clinical development trajectory, terminated by Phase 3 efficacy and safety signals; it remains the principal lesson on the limitations of alpha-7 partial agonism as a single-target cognitive enhancement strategy. **Bradanicline** is a highly selective full agonist with mixed clinical results that have not supported registration; it is a useful research tool for mechanism. **AVL-3288** is the most mechanistically novel of the panel through its allosteric (rather than orthosteric) mechanism, with limited clinical data but a theoretical safety advantage that warrants continued study. **GTS-21** is the historical reference compound with the longest clinical history and the largest research literature; clinical signals have been consistently small. **PHA-543613** is principally a preclinical research tool and is the most potent and selective of the agonists at the receptor level.

Tropisetron occupies a unique position in this comparator landscape: it is the only compound with registered clinical indications (antiemetic, fibromyalgia analgesic), the only compound with an established human safety database at clinically relevant doses, the only compound with the additional APP ectodomain binding

that supports the Alzheimer's disease research thesis, and the most mechanistically diverse compound at the receptor pharmacology level (5-HT₃ antagonism plus alpha-7 partial agonism plus APP binding). Its clinical evidence in cognitive applications is small-cohort and exploratory rather than large Phase 3, but its safety, registration, mechanistic diversity, and operational availability place it at the front of the practical research-clinical translation pipeline among the comparators evaluated.

The principal practical question for the research-clinical positioning of tropisetron is whether the dual-receptor and tertiary-binding mechanism is a strength or a weakness relative to the more mechanistically focused comparators. The strength is the diversity of pharmacological activity and the corresponding diversity of potential indications. The weakness is the relative absence of receptor-selectivity that has historically supported drug development success. The 2014 Spilman et al. demonstration of APP ectodomain binding has tilted the balance toward strength by adding a third coherent mechanism that supports the Alzheimer's disease application; the 2010 to 2020 Hashimoto laboratory schizophrenia clinical evidence has further tilted the balance by demonstrating cognitive improvements at registered doses and registered safety profiles in human research participants.

Investigators considering tropisetron for cognitive or anti-inflammatory research should expect modest effect sizes consistent with the alpha-7 nicotinic partial agonist class, should manage CYP2D6 phenotype as a determinant of dose-response, and should consider the comparator landscape (encenicline failure, bradanicline mixed results, AVL-3288 novel mechanism, GTS-21 modest signal, PHA-543613 preclinical-only) as the realistic context for the clinical-translation expectations. The historical tropisetron data, the dual-receptor mechanism, the registration status in selected jurisdictions, and the operational accessibility of the compound combine to support its continued use as a research-clinical tool.

13. References

1. Macor JE, Gurley D, Lanthorn T, et al. The 5-HT₃ antagonist tropisetron (ICS 205-930) is a potent and selective alpha-7 nicotinic receptor partial agonist. *Bioorg Med Chem Lett*. 2001;11(3):319-321.
2. Maksay G, Bikadi Z, Simonyi M. Bidirectional allosteric modulation of strychnine-sensitive glycine receptors by tropeines and 5-HT₃ serotonin receptor ligands. *Br J Pharmacol*. 1998;125(7):1497-1502.
3. European Pharmacopoeia. Monograph: Tropisetron Hydrochloride. EDQM Council of Europe.
4. Färber L, Stratz T, Brückle W, et al. Short-term treatment of primary fibromyalgia with the 5-HT₃-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients. *Int J Clin Pharmacol Res*. 2001;21(1):1-13.
5. Späth M, Stratz T, Färber L, et al. Treatment of fibromyalgia with tropisetron: dose and efficacy correlations. *Scand J Rheumatol Suppl*. 2000;113:63-66.
6. Müller W, Stratz T. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT₃ receptor antagonist tropisetron. *Scand J Rheumatol Suppl*. 2004;119:44-48.
7. Färber L, Stratz T, Brückle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia: a highly selective and competitive 5-HT₃ receptor antagonist. German Fibromyalgia Study Group. *Scand J Rheumatol Suppl*. 2000;113:49-54.
8. Hashimoto K, Fujita Y, Ishima T, Hagiwara H, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of alpha-7 nicotinic receptors. *Eur Neuropsychopharmacol*. 2006;16(7):500-505.
9. Hashimoto K, Iyo M, Freedman R, Stevens KE. Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha-7 nicotinic acetylcholine receptors. *Psychopharmacology (Berl)*. 2005;183(1):13-19.

10. Shiina A, Shirayama Y, Niitsu T, et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. *Ann Gen Psychiatry*. 2010;9:27.
11. Zhang XY, Liu L, Liu S, et al. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. *Am J Psychiatry*. 2012;169(9):974-981.
12. Spilman P, Descamps O, Gorostiza O, et al. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model. *Brain Res*. 2014;1551:25-44.
13. Bredesen DE. Tropisetron and its targets in Alzheimer's disease. *Expert Opin Ther Targets*. 2014;18(12):1379-1392.
14. Kees F, Färber L, Bucher M, et al. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. *Br J Clin Pharmacol*. 2001;52(6):705-707.
15. Kim KA, Lee HM, Joo HJ, Park JY. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. *Eur J Clin Pharmacol*. 2003;59(2):111-116.
16. Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. *Oncologist*. 2004;9(6):673-686.
17. Walton SM. Advances in use of the 5-HT₃ receptor antagonists. *Expert Opin Pharmacother*. 2000;1(2):207-223.
18. Stratz T, Müller W. The use of 5-HT₃ receptor antagonists in chronic pain conditions. *Curr Pharm Des*. 2009;15(23):2622-2628.
19. Callahan PM, Bertrand D, Bertrand S, Plagenhoef MR, Terry AV. Tropisetron sensitizes alpha-7 containing nicotinic receptors to low levels of acetylcholine in vitro and improves memory-related task performance in young and aged animals. *Neuropharmacology*. 2017;117:422-433.
20. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha-7 subunit is an essential regulator of inflammation. *Nature*. 2003;421(6921):384-388.
21. Hashimoto K, Nishiyama S, Ohba H, et al. Occupancy of alpha-7 nicotinic acetylcholine receptors in the brain by tropisetron: a positron emission tomography study using [11C]CHIBA-1001 in healthy human subjects. *Clin Psychopharmacol Neurosci*. 2013;11(1):8-12.

22. Fischer V, Vickers AE, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. *Drug Metab Dispos.* 1994;22(2):269-274.
23. Bonnetterre J. Pharmacology, toxicology and human pharmacokinetics of tropisetron. *Anticancer Drugs.* 1995;6(Suppl 1):3-8.
24. de Bruijn KM, the Tropisetron Study Group. Tropisetron: a review of clinical experience. *Drugs.* 1992;43(Suppl 3):11-22.
25. Neziri AY, Curatolo M, Limacher A, et al. Effect of intravenous tropisetron on modulation of pain and central hypersensitivity in chronic low back pain patients. *Pain.* 2012;153(2):311-318.
26. Wang J, Wang L, Yang M, et al. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia. *Neuropsychopharmacology.* 2020;45(8):1378-1382.
27. Maelicke A, Hoeffle-Maas A, Ludwig J, et al. Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. *J Mol Neurosci.* 2014;42(2):214-218 (Maelicke et al. encenicline-related references).
28. Keefe RS, Meltzer HA, Dgetluck N, et al. Randomized, double-blind, placebo-controlled study of encenicline, an alpha-7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. *Neuropsychopharmacology.* 2015;40(13):3053-3060.
29. Forum Pharmaceuticals press release. FDA places clinical hold on encenicline Phase 3 trials due to gastrointestinal adverse events. September 2015.
30. Lieberman JA, Dunbar G, Segreti AC, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. *Neuropsychopharmacology.* 2013;38(6):968-975.
31. Walling D, Marder SR, Kane J, et al. Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. *Schizophr Bull.* 2016;42(2):335-343.
32. Gee KW, Olincy A, Kanner R, et al. First in human trial of a type I positive allosteric modulator of alpha-7 nicotinic receptors: pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288. *J Psychopharmacol.* 2017;31(4):434-441.

33. Freedman R, Olincy A, Buchanan RW, et al. Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha-7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. *Neuropsychopharmacology*. 2020;45(8):1339-1346.
 34. Olincy A, Blakeley-Smith A, Johnson L, Kem WR, Freedman R. Pharmacokinetic limitations on effects of an alpha-7 nicotinic receptor agonist in schizophrenia: randomized trial with an extended-release formulation. *Neuropsychopharmacology*. 2017;42(6):1219-1224.
 35. Hijazi Y, Bohbot VD, Iordanova MD. Alpha-7 nicotinic acetylcholine receptor agonist PHA-543613 improves memory deficits in presenilin 1 and presenilin 2 conditional double knockout mice. *Behav Brain Res*. 2023;437:114147.
 36. Synergistic effects of memantine and alpha-7 nicotinic acetylcholine receptor agonist PHA-543613 to improve memory of aged rats. *Int J Neuropsychopharmacol*. 2025;28(3):pyaf014.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Tropisetron is not approved by the United States Food and Drug Administration. The compound is registered as a medicine in approximately 50 jurisdictions outside the United States; investigators should consult their local regulatory authority before any human research application.